Eddie Hickman
Stock Analyst at Guggenheim
(4.49)
# 285
Out of 5,131 analysts
18
Total ratings
68.42%
Success rate
21.88%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Eddie Hickman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PMN ProMIS Neurosciences | Maintains: Buy | $150 → $125 | $8.48 | +1,374.06% | 3 | Nov 18, 2025 | |
| TARS Tarsus Pharmaceuticals | Maintains: Buy | $84 → $87 | $78.21 | +11.24% | 9 | Nov 5, 2025 | |
| OTLK Outlook Therapeutics | Downgrades: Neutral | n/a | $0.60 | - | 4 | Aug 29, 2025 | |
| ZVRA Zevra Therapeutics | Maintains: Buy | $20 → $22 | $8.63 | +154.92% | 1 | Mar 13, 2025 | |
| GHRS GH Research | Initiates: Buy | $32 | $15.55 | +105.79% | 1 | Mar 13, 2025 |
ProMIS Neurosciences
Nov 18, 2025
Maintains: Buy
Price Target: $150 → $125
Current: $8.48
Upside: +1,374.06%
Tarsus Pharmaceuticals
Nov 5, 2025
Maintains: Buy
Price Target: $84 → $87
Current: $78.21
Upside: +11.24%
Outlook Therapeutics
Aug 29, 2025
Downgrades: Neutral
Price Target: n/a
Current: $0.60
Upside: -
Zevra Therapeutics
Mar 13, 2025
Maintains: Buy
Price Target: $20 → $22
Current: $8.63
Upside: +154.92%
GH Research
Mar 13, 2025
Initiates: Buy
Price Target: $32
Current: $15.55
Upside: +105.79%